

Andrea Giustina

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/853312/andrea-giustina-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

208
papers

12,973
citations

63
h-index

109
g-index

230
ext. papers

15,954
ext. citations

6.2
avg, IF

6.89
L-index

#	Paper	IF	Citations
208	Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 23, 133	10.5	1
207	Evaluation of Muscle Mass and Stiffness with Limb Ultrasound in COVID-19 Survivors.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 801133	5.7	0
206	Clinical Biology of the Pituitary Adenoma.. <i>Endocrine Reviews</i> , 2022 ,	27.2	3
205	Malignancy risk in indeterminate thyroid nodules with Hürthle cells: role of autoimmune thyroiditis. <i>Endocrine</i> , 2021 , 75, 823	4	1
204	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 847-875	18.1	48
203	Bone Strain Index predicts fragility fracture in osteoporotic women: an artificial intelligence-based study. <i>European Radiology Experimental</i> , 2021 , 5, 47	4.5	1
202	Occurrence and response to treatment of Graves Disease after COVID vaccination in two male patients. <i>Endocrine</i> , 2021 , 1	4	5
201	Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021 , 35, 101515	6.5	3
200	Hypovitaminosis D and the endocrine phenotype of COVID-19. <i>Endocrine</i> , 2021 , 72, 1-11	4	12
199	Effects of Medical Treatment of Prostate Cancer on Bone Health. <i>Trends in Endocrinology and Metabolism</i> , 2021 , 32, 135-158	8.8	12
198	Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 147-160	10.5	1
197	Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. <i>Endocrine</i> , 2021 , 73, 658-666	4	4
196	Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 1	10.5	18
195	Weight trajectories and abdominal adiposity in COVID-19 survivors with overweight/obesity. <i>International Journal of Obesity</i> , 2021 , 45, 1986-1994	5.5	9
194	Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. <i>Endocrine</i> , 2021 , 72, 597-603	4	14
193	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 1	10.5	0
192	COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. <i>Endocrine</i> , 2021 , 72, 301-316	4	29

191	COVID-19 and the pituitary. <i>Pituitary</i> , 2021 , 24, 465-481	4.3	25
190	The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 445-446	15.2	9
189	Pituitary adenoma: Women's omen?. <i>Endocrine</i> , 2021 , 74, 1-4	4	5
188	Impact of preoperative glycometabolic status on outcomes in cardiac surgery: Systematic review and meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	3
187	Cross-species Association Between Telomere Length and Glucocorticoid Exposure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e5124-e5135	5.6	0
186	International Multicenter Validation Study of the SAGIT [®] Instrument in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3555-3568	5.6	1
185	Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study. <i>Endocrine</i> , 2021 , 71, 59-68	4	9
184	A Pituitary Society update to acromegaly management guidelines. <i>Pituitary</i> , 2021 , 24, 1-13	4.3	50
183	Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e602-e614	5.6	34
182	Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. <i>Endocrine</i> , 2021 , 71, 9-13	4	23
181	The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy. <i>JBMR Plus</i> , 2021 , 5, e10440	3.9	6
180	Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. <i>Endocrine</i> , 2021 , 71, 273-280	4	9
179	Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. <i>Endocrine</i> , 2021 , 71, 267-269	4	16
178	Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. <i>European Journal of Endocrinology</i> , 2021 , 184, 217-229	6.5	10
177	Resistance to first-generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly. <i>Clinical Endocrinology</i> , 2021 , 95, 849-855	3.4	2
176	One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2021 , 185, C1-C7	6.5	3
175	COVID-19 and hypopituitarism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 1	10.5	5
174	Vitamin D levels associate with blood glucose and BMI in COVID-19 patients predicting disease severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	8

173	Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. <i>Endocrine</i> , 2021 , 74, 219-225	4	5
172	Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19. <i>Diabetes and Metabolism</i> , 2021 , 47, 101268	5.4	8
171	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 1201	10.5	5
170	Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , 2020 , 4, e10417	3.9	51
169	Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection. <i>Endocrine</i> , 2020 , 68, 253-254		19
168	The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 527-536	10.5	7
167	Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. <i>Endocrine</i> , 2020 , 68, 475-478	4	81
166	Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors. <i>Endocrine</i> , 2020 , 69, 604-614	4	2
165	Consensus statement from 2 International Conference on Controversies in Vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 89-116	10.5	97
164	Acromegaly and Vertebral Fractures: Facts and Questions. <i>Trends in Endocrinology and Metabolism</i> , 2020 , 31, 274-275	8.8	20
163	Hyperprolactinemia and bone. <i>Pituitary</i> , 2020 , 23, 314-321	4.3	14
162	Endocrine and metabolic aspects of the COVID-19 pandemic. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 495-507	10.5	75
161	Patient-Centered Outcomes with Pituitary and Parasellar Disease. <i>Neuroendocrinology</i> , 2020 , 110, 882-888	9.6	2
160	COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. <i>Endocrine</i> , 2020 , 68, 2-5	4	135
159	Paracentral acute middle maculopathy in central retinal vein occlusion complicating AL-amyloidosis. <i>Retinal Cases and Brief Reports</i> , 2020 ,	1.1	2
158	MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. <i>European Journal of Endocrinology</i> , 2020 , 183, R133-R147	6.5	143
157	MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
156	Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells. <i>Pituitary</i> , 2020 , 23, 223-231	4.3	3

155	Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 5-16	10.5	64
154	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. <i>Pituitary</i> , 2020 , 23, 476-477	4.3	12
153	Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. <i>Clinical Nutrition</i> , 2020 , 39, 2368-2388	5.9	89
152	Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	11
151	Pituitary Tumors Centers of Excellence. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020 , 49, 553-564	5.5	11
150	Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19. <i>Endocrine</i> , 2020 , 70, 463-464	4	17
149	Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. <i>Trends in Endocrinology and Metabolism</i> , 2020 , 31, 918-927	8.8	31
148	Are women with osteoporosis treated with denosumab at risk of severe COVID-19?. <i>Endocrine</i> , 2020 , 70, 203-205	4	18
147	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 667-678	10.5	67
146	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	29
145	Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
144	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	88
143	Risk of vertebral fractures in hypoparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019 , 20, 295-302	10.5	12
142	A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement. <i>Pituitary</i> , 2019 , 22, 569-573	4.3	41
141	Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. <i>JAMA Network Open</i> , 2019 , 2, e1911080	10.4	11
140	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 20	51.1	128
139	ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2019 , 66, 320-329	1.3	4
138	The Changing Clinical Spectrum of Hypophysitis. <i>Trends in Endocrinology and Metabolism</i> , 2019 , 30, 590-608	6.8	22

137	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT validation study. <i>Pituitary</i> , 2019 , 22, 476-487	4.3	13
136	Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. <i>Endocrine</i> , 2019 , 66, 699-700	4	15
135	OR32-6 Pre-Surgical GH Levels Predict the Risk of Morphometric Vertebral Fracture, Which Is an Early and Frequent Event in the Natural History of Acromegaly. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
134	MON-529 Body Mass Index Predicts Resistance To Active Vitamin D In Patients With Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
133	Quality of Life in Patients With Cushing Disease. <i>Frontiers in Endocrinology</i> , 2019 , 10, 862	5.7	17
132	Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome. <i>Endocrine</i> , 2019 , 63, 225-230	4	9
131	Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , 2019 , 40, 1109-1151	27.2	304
130	High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 956-964	5.6	28
129	Quality of Life in Cushing disease: A long term issue?. <i>Annales D'Endocrinologie</i> , 2018 , 79, 132-137	1.7	14
128	Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. <i>Pituitary</i> , 2018 , 21, 302-308	4.3	16
127	Bone safety of dual-release hydrocortisone in patients with hypopituitarism. <i>Endocrine</i> , 2018 , 60, 528-534		16
126	The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 431-438	5.2	27
125	Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals. <i>Molecular and Cellular Endocrinology</i> , 2018 , 470, 60-74	4.4	13
124	Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. <i>Endocrine</i> , 2018 , 59, 449-453	4	16
123	A Consensus Statement on acromegaly therapeutic outcomes. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 552-561	15.2	216
122	MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D. <i>European Journal of Endocrinology</i> , 2018 , 179, R239-R259	6.5	33
121	Treatment of hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 32, 955-964	6.5	14
120	High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma. <i>Journal of the Endocrine Society</i> , 2018 , 2, 1089-1099	0.4	12

119	Pituitary Diseases and Bone. <i>Endocrine Reviews</i> , 2018 , 39, 440-488	27.2	68
118	Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2194-2207	3.8	120
117	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017 , 97, 147-152	4.7	21
116	Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. <i>Endocrine</i> , 2017 , 57, 179-182	4	1
115	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 577-589	5.2	39
114	Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management. <i>Drugs</i> , 2017 , 77, 829-842	12.1	86
113	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2454-2464	5.6	29
112	Diabetes in Cushing Disease. <i>Current Diabetes Reports</i> , 2017 , 17, 32	5.6	22
111	MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. <i>European Journal of Endocrinology</i> , 2017 , 177, R13-R26	6.5	27
110	White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study. <i>Pituitary</i> , 2017 , 20, 340-348	4.3	19
109	Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1679-1689	4	14
108	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. <i>Pituitary</i> , 2017 , 20, 489-498	4.3	157
107	Acromegalic osteopathy. <i>Pituitary</i> , 2017 , 20, 63-69	4.3	24
106	Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study. <i>BioMed Research International</i> , 2017 , 2017, 2061935	3	15
105	Prevalence of acromegaly in patients with symptoms of sleep apnea. <i>PLoS ONE</i> , 2017 , 12, e0183539	3.7	9
104	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. <i>European Journal of Endocrinology</i> , 2017 , 177, R231-R248	6.5	42
103	Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. <i>Clinical Endocrinology</i> , 2016 , 85, 717-724	3.4	12
102	Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2016 , 63, 397-408		18

101	New medical therapies of acromegaly. <i>Growth Hormone and IGF Research</i> , 2016 , 30-31, 58-63	2	8
100	Brain metabolite abnormalities in ventromedial prefrontal cortex are related to duration of hypercortisolism and anxiety in patients with Cushing β syndrome. <i>Endocrine</i> , 2016 , 53, 848-56	4	16
99	New oral anticoagulants and pituitary apoplexy. <i>Pituitary</i> , 2016 , 19, 232-4	4.3	11
98	Bone and Joint Disorders in Acromegaly. <i>Neuroendocrinology</i> , 2016 , 103, 86-95	5.6	44
97	SAGIT \square : clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. <i>Pituitary</i> , 2016 , 19, 39-49	4.3	37
96	Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. <i>Endocrine</i> , 2016 , 52, 103-10	4	46
95	The role of patient education in the prevention and management of type 2 diabetes: an overview. <i>Endocrine</i> , 2016 , 53, 18-27	4	78
94	Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2 diabetes. <i>Journal of Geriatric Cardiology</i> , 2016 , 13, 552-6	1.7	3
93	Current and future medical treatments for patients with acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1631-42	4	20
92	Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2016 , 27, 470-483	8.8	66
91	The Modern Criteria for Medical Management of Acromegaly. <i>Progress in Molecular Biology and Translational Science</i> , 2016 , 138, 63-83	4	25
90	High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. <i>Endocrine</i> , 2016 , 54, 532-542	4	34
89	Reduced DNA methylation of FKBP5 in Cushing β syndrome. <i>Endocrine</i> , 2016 , 54, 768-777	4	26
88	Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1699-708	5.6	114
87	Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. <i>Endocrine</i> , 2015 , 50, 756-63	4	22
86	Cardiovascular risk and white matter lesions after endocrine control of Cushing β syndrome. <i>European Journal of Endocrinology</i> , 2015 , 173, 765-75	6.5	29
85	Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?. <i>Acta Diabetologica</i> , 2015 , 52, 433-43	3.9	12
84	Parathyroid hormone pulsatility: physiological and clinical aspects. <i>Bone Research</i> , 2015 , 3, 14049	13.3	29

83	Dyslipidemia and chronic inflammation markers are correlated with telomere length shortening in Cushing β syndrome. <i>PLoS ONE</i> , 2015 , 10, e0120185	3.7	25
82	Pituitary diseases and bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015 , 44, 171-80	5.5	30
81	Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 384-94	5.6	100
80	Expert consensus document: A consensus on the medical treatment of acromegaly. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 243-8	15.2	255
79	Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. <i>Endocrine Reviews</i> , 2014 , 35, 234-81	27.2	131
78	Small cerebellar cortex volume in patients with active Cushing β syndrome. <i>European Journal of Endocrinology</i> , 2014 , 171, 461-9	6.5	45
77	Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 18-29	5.6	99
76	Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?. <i>PLoS ONE</i> , 2014 , 9, e104174	3.7	28
75	Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. <i>European Journal of Endocrinology</i> , 2014 , 170, 893-9	6.5	28
74	Telomere length analysis in Cushing β syndrome. <i>European Journal of Endocrinology</i> , 2014 , 171, 21-9	6.5	20
73	Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern. <i>European Endocrinology</i> , 2014 , 10, 79-83	3.4	3
72	A consensus on the diagnosis and treatment of acromegaly complications. <i>Pituitary</i> , 2013 , 16, 294-302	4.3	210
71	Glucocorticoids and the regulation of growth hormone secretion. <i>Nature Reviews Endocrinology</i> , 2013 , 9, 265-76	15.2	113
70	Vertebral fractures in patients with acromegaly: a 3-year prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3402-10	5.6	104
69	Hippocampal dysfunction in cured Cushing β syndrome patients, detected by (1) H-MR-spectroscopy. <i>Clinical Endocrinology</i> , 2013 , 79, 700-7	3.4	27
68	Improving Quality of Life in Patients with Pituitary Tumours. <i>European Endocrinology</i> , 2013 , 9, 32-36	3.4	4
67	New understanding and treatments for osteoporosis. <i>Endocrine</i> , 2012 , 41, 58-69	4	113
66	Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing β syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 663-71	5.6	114

65	Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. <i>European Journal of Endocrinology</i> , 2012 , 167, 865-72	6.5	18
64	Meta-analysis on the effects of octreotide on tumor mass in acromegaly. <i>PLoS ONE</i> , 2012 , 7, e36411	3.7	128
63	Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment. <i>Expert Review of Endocrinology and Metabolism</i> , 2012 , 7, 55-62	4.1	12
62	Current management practices for acromegaly: an international survey. <i>Pituitary</i> , 2011 , 14, 125-33	4.3	72
61	High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. <i>Pituitary</i> , 2011 , 14, 299-306	4.3	52
60	Vertebral fractures in males with prolactinoma. <i>Endocrine</i> , 2011 , 39, 288-93	4	70
59	Influence of diabetes mellitus on vertebral fractures in men with acromegaly. <i>Endocrine</i> , 2011 , 40, 102-84		43
58	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. <i>European Journal of Endocrinology</i> , 2011 , 164, 341-7	6.5	34
57	A consensus on criteria for cure of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3141-8	5.6	572
56	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 343-6	5.2	29
55	Drug-induced osteoporosis: mechanisms and clinical implications. <i>American Journal of Medicine</i> , 2010 , 123, 877-84	2.4	189
54	Treatment of Cushing disease: overview and recent findings. <i>Therapeutics and Clinical Risk Management</i> , 2010 , 6, 505-16	2.9	46
53	Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. <i>Pituitary</i> , 2010 , 13, 60-7	4.3	73
52	Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2015-22	5.6	59
51	Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3365-71	5.6	114
50	High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. <i>European Journal of Endocrinology</i> , 2009 , 161, 331-8	6.5	84
49	Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1500-8	5.6	161
48	Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. <i>Bone</i> , 2009 , 45, 784-8	4.7	64

47	Hyperprolactinemia and prolactinomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 67-99, viii	5.5	154
46	Growth hormone, insulin-like growth factors, and the skeleton. <i>Endocrine Reviews</i> , 2008 , 29, 535-59	27.2	597
45	Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 731-8	5.2	9
44	The management of the patient with acromegaly and headache: a still open clinical challenge. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 919-24	5.2	13
43	Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 820-38	5.2	71
42	Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. <i>European Journal of Endocrinology</i> , 2008 , 159, 533-40	6.5	90
41	Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2746-50	5.6	71
40	Prevalence of vertebral fractures in men with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4649-55	5.6	113
39	Pituitary testing: a reappraisal. <i>Pituitary</i> , 2008 , 11, 113-4	4.3	1
38	Glucocorticoid-induced osteoporosis: pathophysiology and therapy. <i>Osteoporosis International</i> , 2007 , 18, 1319-28	5.3	757
37	Mechanisms of anabolic therapies for osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 357, 905-16	59.2	490
36	Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1743-7	5.6	115
35	Development of Graves hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto's hypothyroidism. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 288-90	5.2	5
34	Resistance to somatostatin analogs in acromegaly: an evolving concept?. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 86-93	5.2	57
33	High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. <i>Bone</i> , 2006 , 39, 253-9	4.7	249
32	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. <i>Clinical Endocrinology</i> , 2006 , 65, 265-73	3.4	558
31	Growth hormone deficiency in the adult. <i>Pituitary</i> , 2006 , 9, 305-11	4.3	53
30	Clinical review: Growth hormone and cardiovascular risk factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1864-70	5.6	107

29	Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1837-44	6.3	123
28	Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. <i>European Journal of Endocrinology</i> , 2005 , 152, 199-205	6.5	57
27	Acromegalic Patients Show the Presence of Hypertrophic Remodeling of Subcutaneous Small Resistance Arteries. <i>Hypertension</i> , 2004 , 43, 561-565	8.5	51
26	Cushing's syndrome and bone. <i>Pituitary</i> , 2004 , 7, 249-52	4.3	101
25	Perspectives on glucocorticoid-induced osteoporosis. <i>Bone</i> , 2004 , 34, 593-8	4.7	186
24	Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, 359-63	5.2	14
23	Acromegaly Consensus: The Next Steps. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1913-1914	5.1	10
22	Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis. <i>Frontiers of Hormone Research</i> , 2002 , 30, 150-64	3.5	3
21	Consensus Document on substitution therapy with testosterone in hypoandrogenic elderly men. <i>Aging Clinical and Experimental Research</i> , 2002 , 14, 439-64	4.8	7
20	The negative role of subclinical thyrotoxicosis on the outcome of hospitalized geriatric patients. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 64-5	5.2	3
19	Glucocorticoid-induced osteoporosis: summary of a workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5681-5	5.6	87
18	Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 4567-75	5.6	71
17	Criteria for cure of acromegaly: a consensus statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 526-9	5.6	727
16	Acute and chronic galanin administration decreases hypothalamic galanin synthesis in both male and female adult rats: evidence for a long-loop galanin autofeedback. <i>Metabolism: Clinical and Experimental</i> , 2000 , 49, 778-83	12.7	2
15	Glucocorticoid-induced osteoporosis. <i>Trends in Endocrinology and Metabolism</i> , 2000 , 11, 79-85	8.8	98
14	Role of growth hormone in chronic heart failure. Therapeutic implications. <i>Drugs</i> , 2000 , 60, 711-9	12.1	22
13	Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3260-7	5.6	44
12	Feedback Regulation of Growth Hormone Secretion 1999 , 299-327		

11	Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. <i>Diabetes</i> , 1998 , 47, 423-30	0.9	33
10	The pharmacological aspects of the treatment of acromegaly. <i>Pharmacological Research</i> , 1996 , 34, 247-68	0.2	20
9	Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog. <i>Endocrine Research</i> , 1996 , 22, 159-74	1.9	7
8	Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. <i>American Journal of Cardiology</i> , 1995 , 75, 1042-7	3	64
7	Effects of methimazole treatment on growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism. <i>European Journal of Endocrinology</i> , 1990 , 123, 613-8	6.5	8
6	Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 580-4	5.6	48
5	Effects of calcitonin on GH response to pyridostigmine in combination with hGHRH (1-29) NH ₂ in normal adult subjects. <i>Clinical Endocrinology</i> , 1990 , 33, 375-80	3.4	8
4	Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 1486-90	5.6	28
3	Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989 , 68, 120-4	5.6	59
2	Leptin Regulates GH Gene Expression and Secretion and Nitric Oxide Production in Pig Pituitary Cells		27
1	COVID-19 and hypopituitarism. Experience from an endocrine center in a high-impact area. <i>Endocrine Abstracts</i> ,		2